ADMET & DMPK

ADMET & DMPK

Uric acid transporter inhibitors for gout

Yazarlar: Philip K. Tan, Jeffrey N. Miner

Cilt 5 , Sayı 2 , 2017 , Sayfalar 59-74

Konular:-

DOI:10.5599/admet.5.2.387

Anahtar Kelimeler:Gout,Hyperuricemia,Uricase,URAT1,Coevolution,Urate transporters for urate homeostasis

Özet: Gout is a common inflammatory arthritis that is caused by chronically-elevated serum uric acid (sUA) levels (hyperuricemia). In humans, sUA levels are predominantly controlled by a variety of transporters that mediate the elimination of uric acid through the kidneys and intestines, a process that is altered in most gout patients. In this review, we highlight our current understanding of uric acid handling in healthy individuals and gout patients, therapies for gout that target uric acid transporters, and the mechanism of other therapies that alter sUA levels through interactions with uric acid transporters.

ATIFLAR
Atıf Yapan Eserler
Henüz Atıf Yapılmamıştır
KAYNAK GÖSTER
BibTex
KOPYALA
@article{2017, title={Uric acid transporter inhibitors for gout}, volume={5}, number={59–74}, publisher={ADMET & DMPK}, author={Philip K. Tan, Jeffrey N. Miner}, year={2017} }
APA
KOPYALA
Philip K. Tan, Jeffrey N. Miner. (2017). Uric acid transporter inhibitors for gout (Vol. 5). Vol. 5. ADMET & DMPK.
MLA
KOPYALA
Philip K. Tan, Jeffrey N. Miner. Uric Acid Transporter Inhibitors for Gout. no. 59–74, ADMET & DMPK, 2017.
Atıf Görüntüle
PDF Görüntüle
Kaynak Görüntüle
Paylaş
Dergi Bilgileri